Butler John P., Director, added 5,000 shares of Zynerba Pharmaceuticals, Inc. (ZYNE) to its portfolio at the rate of $6.43 per share valuing $32,153 on Aug 22. The insider has now 5,000 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Zynerba Pharmaceuticals, Inc. (ZYNE) was $13.63. Currently, the 1st Resistance Point for this stock is $14.14, with a 2nd Resistance Point sitting at $14.65. Meanwhile, this company’s stock has a 1st Support Level at $13.09 and a 2nd Support Level at $12.55. Zynerba Pharmaceuticals, Inc. (ZYNE) stock has gained $2.79, or 25.74%, in the past five days. In the last full month, these shares have gained $0.69, or 5.33%. In the past three months, this stock’s price has risen by $8.53, or 167.25%. This year-to-date, Zynerba Pharmaceuticals, Inc. (ZYNE) shares have gained $10.66, or 358.92%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Zynerba Pharmaceuticals, Inc. (ZYNE) stock, 80% of short-term indicators suggest that these shares are a “ Hold .” Meanwhile, 75% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 67% of long-term indicators suggest that this stock is a “ Buy .”
With 21,075 K shares outstanding, this company currently has a market capitalization of $284,934K. Zynerba Pharmaceuticals, Inc. (ZYNE) generates $90 K in annual sales, amounting to annual net income of -$39,910 K. This stock has generated a 1-Year Total Return of 20.51%, a 3-Year Total Return of 80.53%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, Zynerba Pharmaceuticals, Inc. (ZYNE) reported earnings of -$0.47 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.49 per share, representing a 0.02 difference and -3.75% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.44 represented a 0.21 difference from the consensus estimate calling for -$0.65 per share, which was a -31.89% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.50 per share. This estimate came from a total of 3 Wall Street Analysts. Of those market experts, the high estimate was -$0.46 and the low estimate was -$0.53. In the year-ago quarter, Zynerba Pharmaceuticals, Inc. (ZYNE) generated per-share earnings of -$0.89. If the analysts are correct about the current quarter’s earnings, the growth will be +43.82% .
Turning our focus now to insider trading activity, there have been 0 purchases (0 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 1 insider buys amounting to 3,600 shares and 0 insider sales amounting to 0 shares. In the past full year, 6 insider purchases were made (involving 39,718 shares) and 0 insider sell-offs equivalent to 0 shares.
Moving onto liquidity, Zynerba Pharmaceuticals, Inc. (ZYNE) has a Current Ratio of 6.86, a Quick Ratio of 6.86 and a Cash Ratio of 6.14.